公司资料
Day One Biopharmaceuticals 股价、新闻与催化剂
- 股票代码:
- DAWN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
21.53 USD (+0.19%)
收盘价
最后更新: 2026年4月22日
2.22B USD
市值
股价为何变动
Current closing-price context is not available for DAWN.
公司概览
Pediatric and Rare Oncology
Day One Biopharmaceuticals develops targeted therapies for cancers affecting children and adults. The company was founded around pediatric oncology and is expanding into additional rare tumor types.
OJEMDA
OJEMDA is a type II RAF inhibitor approved for relapsed or refractory pediatric low-grade glioma with an activating RAF alteration. It provides Day One’s commercial foundation and is being studied in the frontline setting.
FIREFLY Program
FIREFLY-1 supported approval and continues to provide long-term durability data. FIREFLY-2 is a pivotal Phase 3 trial evaluating OJEMDA in newly diagnosed pediatric low-grade glioma.
Emi-Le
Emi-Le is a B7-H4-directed antibody-drug conjugate acquired with Mersana Therapeutics. It is in Phase 1 development for adenoid cystic carcinoma and broadens Day One into rare adult cancers.
DAY301
DAY301 is a PTK7-targeted antibody-drug conjugate in Phase 1a dose escalation. The program adds a second ADC mechanism and another opportunity beyond the OJEMDA franchise.
未来催化剂
- Completion of enrollment in the Phase 3 FIREFLY-2 trial expected in the first half of 2026.
- Updated Phase 1 Emi-Le data expected in mid-2026.
- Initial Phase 1a DAY301 data and program update expected in the second half of 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。